The role of aldose reductase in the development of peripheral neuropathy as a late complication of diabetes is discussed and preliminary results of a double blind trial of cyclandelate and placebo in the treatment of diabetic peripheral neuropathy are presented. Examination of the data from the first 16 patients who have completed the study indicates improvement in nerve conductance in the cyclandelate treated group. The possible explanation for the improvement is discussed. Definite conclusions regarding the value of cyclandelate in the treatment of diabetic peripheral neuropathy will have to await the completion of the study.
|Number of pages||7|
|Journal||British Journal of Clinical Practice|
|Issue number||6 SUPPL. 34|
|Publication status||Published - 1984|
ASJC Scopus subject areas